Physician profile
Erich Bryan Groos
NPI 1720084601
$4,695.13
in general payments reported to CMS, 2019-2025
27 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $415 · 2021: $553 · 2022: $658 · 2023: $560 · 2024: $768 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $564.18 | 2024-2025 | Vevye |
| Allergan, INC. | $552.99 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $392.24 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $348.34 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $304.32 | 2019-2025 | |
| Biotissue Holdings INC. | $296.74 | 2019-2025 | |
| Glaukos Corporation | $262.09 | 2020-2025 | Photrexa Viscous and Photrexa |
| Alcon Vision LLC | $211.69 | 2019-2024 | Rocklatan |
| Rxsight INC | $209.74 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $200.28 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $195.72 | 2019-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Dompe US, INC. | $166.10 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $142.83 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $121.82 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $119.43 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $98.77 | 2019-2021 | |
| Oyster Point Pharma, INC. | $91.53 | 2022-2025 | Tyrvaya |
| Shire North American Group INC | $86.16 | 2019 | |
| Aerie Pharmaceuticals, INC. | $76.65 | 2019-2021 | |
| Thea Pharma INC. | $57.02 | 2023-2025 | Iyuzeh |
| Tearlab Corp | $52.82 | 2023-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Kala Pharmaceuticals, INC. | $36.44 | 2021 | |
| Nova Eye, INC. | $30.51 | 2023 | |
| Akorn, INC. | $22.40 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $21.30 | 2025 | |
| Ocular Therapeutix, INC. | $19.35 | 2024 | Dextenza |
| Mallinckrodt Hospital Products INC. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erich Groos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.